Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3

TS. Tavares, J. Hofman, A. Lekešová, J. Želazková, V. Wsól,

. 2020 ; 12 (11) : . [pub] 20201026

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001897

Grantová podpora
CZ.02.1.01/0.0/0.0/18_069/0010046 Ministerstvo Školství, Mládeže a Tělovýchovy
20-20414Y Grantová Agentura České Republiky

Olaparib is a potent poly (ADP-ribose) polymerase inhibitor currently used in targeted therapy for treating cancer cells with BRCA mutations. Here we investigate the possible interference of olaparib with daunorubicin (Daun) metabolism, mediated by carbonyl-reducing enzymes (CREs), which play a significant role in the resistance of cancer cells to anthracyclines. Incubation experiments with the most active recombinant CREs showed that olaparib is a potent inhibitor of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Subsequent inhibitory assays in the AKR1C3-overexpressing cellular model transfected human colorectal carcinoma HCT116 cells, demonstrating that olaparib significantly inhibits AKR1C3 at the intracellular level. Consequently, molecular docking studies have supported these findings and identified the possible molecular background of the interaction. Drug combination experiments in HCT116, human liver carcinoma HepG2, and leukemic KG1α cell lines showed that this observed interaction can be exploited for the synergistic enhancement of Daun's antiproliferative effect. Finally, we showed that olaparib had no significant effect on the mRNA expression of AKR1C3 in HepG2 and KG1α cells. In conclusion, our data demonstrate that olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001897
003      
CZ-PrNML
005      
20210126092726.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers12113127 $2 doi
035    __
$a (PubMed)33114555
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tavares, Tássia S $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
245    10
$a Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3. / $c TS. Tavares, J. Hofman, A. Lekešová, J. Želazková, V. Wsól,
520    9_
$a Olaparib is a potent poly (ADP-ribose) polymerase inhibitor currently used in targeted therapy for treating cancer cells with BRCA mutations. Here we investigate the possible interference of olaparib with daunorubicin (Daun) metabolism, mediated by carbonyl-reducing enzymes (CREs), which play a significant role in the resistance of cancer cells to anthracyclines. Incubation experiments with the most active recombinant CREs showed that olaparib is a potent inhibitor of the aldo-keto reductase 1C3 (AKR1C3) enzyme. Subsequent inhibitory assays in the AKR1C3-overexpressing cellular model transfected human colorectal carcinoma HCT116 cells, demonstrating that olaparib significantly inhibits AKR1C3 at the intracellular level. Consequently, molecular docking studies have supported these findings and identified the possible molecular background of the interaction. Drug combination experiments in HCT116, human liver carcinoma HepG2, and leukemic KG1α cell lines showed that this observed interaction can be exploited for the synergistic enhancement of Daun's antiproliferative effect. Finally, we showed that olaparib had no significant effect on the mRNA expression of AKR1C3 in HepG2 and KG1α cells. In conclusion, our data demonstrate that olaparib interferes with anthracycline metabolism, and suggest that this phenomenon might be utilized for combating anthracycline resistance.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hofman, Jakub $u Department of Pharmacology and Toxicology, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Lekešová, Alžběta $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Želazková, Jana $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Wsól, Vladimír $u Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 11 (2020)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33114555 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092722 $b ABA008
999    __
$a ind $b bmc $g 1614060 $s 1122181
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 12 $c 11 $e 20201026 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a CZ.02.1.01/0.0/0.0/18_069/0010046 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a 20-20414Y $p Grantová Agentura České Republiky
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace